Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story. (17th November 2022)

• Record Type: Journal Article
• Authors: Panagopoulos, Periklis; Petrakis, Vasilis; Trypsianis, Grigorios; Papazoglou, Dimitrios
• Is Part Of: Journal of chemotherapy. Volume 34:Number 8(2022)
• Page Start: 550
• Page End: 553
• Publication Date: 2022-11-17
• Subjects: COVID-19 -- SARS-CoV-2 -- remdesivir -- outpatient treatment -- antiviral agent; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1080/1120009X.2022.2099693
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract: A number of treatment options have been evaluated in order to prevent the severe progression of COVID-19 pneumonia eventually in patients with increased risk due to comorbidities. Remdesivir for a 3-day outpatient course has been associated with a significant lower risk of hospitalization or death. A matched-pair retrospective study was conducted in Department of Infectious Diseases of University General Hospital of Alexandroupolis in order to evaluate the role of remdesivir and vaccination in preventing severe clinical outcome. Nonhospitalized vaccinated patients with a 3-day course of remdesivir had a 75% lower possibility of hospitalization and 95% of respiratory failure. Nobody was intubated or died and the duration of hospital stay was limited (4 day s vs. 10 days). Vaccination and a 3-day course of remdesivir in high risk nonhospitalized patients prevented significantly severe clinical progress of COVID-19 pneumonia.